ArticleMolecular brain2026
StitchR-based dual-AAV delivery strategies enable efficient transduction of defined neural cell populations.
Article in Molecular brain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Dual adeno-associated virus (AAV) vector reconstitution has become an indispensable technique for delivering large genes in neuroscience and gene therapy. A novel technology termed StitchR addresses the challenge of low efficiency in dual-AAV reconstruction, yet related tools enabling targeted gene delivery to specific neural cell populations remain insufficiently developed. Herein, we developed four StitchR-based dual-viral reconstitution strategies by combining high-efficiency AAV serotypes with neuron- or glia-specific promoters. Specifically, the AAV11-hSyn-driven StitchR strategy achieved specific transduction of local neurons and their upstream projection neurons (≥ 94.44% specificity); the AAV11-GfaABC1D-driven strategy realized astrocyte-specific transduction (approximately 98.25% specificity); and the AAV11-mIBA1-driven strategy enabled microglia-specific transduction (100% specificity). Furthermore, by incorporating the blood-brain barrier (BBB)-penetrating AAVhu.32-PLUS into the hSyn-driven system, we established a modified strategy that allows brain-wide neuronal transduction. Finally, we confirmed that the StitchR-based dual-viral reconstitution strategy can achieve efficient functional reconstitution of large transgenes in neural cells. Collectively, these dual-AAV delivery strategies expand the valuable AAV toolbox and offer crucial technical support for targeted delivery of large transgenes to defined neural cell populations, holding great significance for basic neuroscience research and potential therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.